Panel Discussion Please join us for a panel discussion on the social impact of cancer and how it affects patients, providers, clinicians, and researchers alike. We are fortunate to feature Leslie Hammersmith (moderator), Jennifer Smith, and Patience Anders from the local Young Survival Coalition, as well as an oncology nurse navigator, clinician, and researcher (names TBA). This diverse panel will discuss themes surrounding cancer diagnosis, care, and research, and we welcome the audience to contribute and participate throughout the event. Issues to be discussed include: (1) Patient Experience, (2) Clinical Strategies, (3) Research Motivation. Truly, this will be an informative and exploratory event for participants of all backgrounds. We hope this panel discussion will result in a highly interactive and dynamic dialogue between the panelists and members of the audience.
I have some questions here.
I want to give each of you three to five minutes
just to talk a little, just pick a story
about your background, why you're doing what you're doing.
And if you could, in that story,
let us know how cancer research and literature
have impacted that for the patients.
How important has that been for you
throughout your cancer experience?
For Louise, does cancer research and literature,
how does that, does that come into play at all in your role?
And so, please describe your role too.
And for the oncologist, obviously, and the researcher.
So, the media, we talked a little bit about media outlets
and having more access to information and studies.
And how does that play a role,
or how has it impacted your relationship with patients?
So, if you could use that in your story for the researcher.
Is there a feedback loop?
For example, as you, as the researcher is out there
and you see what's going on, how does that impact
what you choose to do in your lab and your motivations?
So, if you want, do you want to start, Jen?
Sure, sure.
Told a little bit about my story,
but I'll try and talk quick,
since I know we're short on time.
You guys all have very impressive titles here.
I've got to say, Leslie may be at 65%,
and I think I'm about at 30% understanding today.
My title would be PCP, Professional Cancer Patient.
I was diagnosed with breast cancer in 2007
at the age of 30, underwent a lumpectomy,
six months of treatment, and then radiation,
and three months later found out
I had a recurrence and foam mats.
So, metastatic breast cancer at the age of 31.
My son was almost two.
Statistically, I believe average life expectancy
is two and a half years.
So, my goal was to see him go to kindergarten,
which will hopefully happen this fall.
To answer Leslie's question, though,
and I alluded to this earlier,
I spend days and days and days and hours
making phone calls and looking for clinical trials
that I may be eligible for.
I'm in contact with NCI,
looking what trials are available there.
I'm in contact with a cancer center down in Texas
and seeing what I'm eligible for.
Luckily, we have Indy and Chicago and St. Louis
all right here within our region.
There are lots of opportunities there.
When I was first diagnosed, I was eligible for a CT scan.
I did fall into one of the arms
that would require daily shots
to loosen my blood cells,
but having a little one at home,
I did still have needles.
I had nothing to do with my own fear of needles.
I was too worried that my front line would get into them,
so I did not do the clinical trial,
and now I'm picking myself for that,
but looking at options.
So I heavily do research on what's out there,
definitely watching Twitter and Facebook
and finding Staley and checking all the websites
to see what's up and coming.
My name is Kayshan Sanders,
and like Jen, I'm a member of the local online SC,
and that's how we met.
My story is that almost exactly three years ago this month,
I was diagnosed with breast cancer at the age of 42.
In my case, I was ER positive, PR positive,
and HER2 negative,
so that's considered one of the best diagnoses to get,
and I consider myself very lucky.
Now I have my treatment.
I did have a stage two,
so they did find it in my sentinel lymph node,
and that, it was microscopic,
they had to dig around for it,
but they did find it,
so that put me into an aggressive treatment protocol,
and so I had the adrenomycin for treatments of that
followed by total treatment for taxol,
followed by radiation.
It took about a year to get through all of that.
I had a lumpectomy,
and today I'm met.
There's no evidence of disease.
I feel like it's all behind me,
and I'm reminded of it
because I take Tamoxifen every day.
I'm two years into that,
and I have my regular follow-ups with my oncologist,
but I've gone on with my life,
and there are some kind of residual effects sometimes.
I wonder, you know, the chemo,
I'm forgetful.
I hear a lot about chemo break.
I don't know if there's anything to that or not,
but otherwise I'm feeling pretty good,
and I feel, I was not part of the clinical trial
because my facility that I was treated at
didn't offer anything like that,
so I would have been interested, I think,
had I had the opportunity,
but it apparently worked for me,
so I'm not gonna complain.
Thank you.
My name's John McDonald,
and I'm supposed to be representing cancer researchers.
May not be a good choice
because my story's a little bit unusual.
I spent most of my academic life
doing molecular evolution,
and at the age of 56, I got contact,
and I was doing pretty well,
publications in Nature, NAS and stuff.
The age of 56, I got contacted
by a cancer surgeon in Atlanta
who was specializing in ovarian cancer,
and he had started an ovarian cancer institute,
and he wanted, he asked me if I would join him
in doing the research arm of that.
I had no background in cancer biology at that time.
It was one of those things in life
where you say yes to something you don't know
really why you said yes to it at the time,
but it changed my life completely.
So for the last eight years,
I've been devoted to cancer research,
so even though I'm now 64,
I've only been in this business for about eight years.
But I think one of the reasons I got into it
was I kind of had the same feeling that Leslie had,
that it may be opportunities for different perspectives
on cancer research, new approaches,
and I thought that with the years that I had left to work,
it might be possible for me to bring some new perspectives
into the area of cancer research.
I think one of the things that has been good for us,
and we started this, this surgeon started
an ovarian cancer institute,
which is a non-profit organization.
We came into it, the only money that we had going
was money that was donated from foundations
or patients, grateful patients and things like that.
So we actually, from the very beginning,
spent a lot of time bringing patients into the lab.
Part of it was really, to be honest, fundraising.
But a good amount of our effort goes into translating
the kind of work we're doing on a level
that's understood by the patients.
And we encourage the patients that come into our lab,
probably over, about every month we must have on average
about 10 cancer patients, ovarian cancer patients
that come in to tour our lab.
I think it's very good for the patients,
for them to see what we're doing.
It helps them to go out and advocate better
for the importance of cancer research.
I think it's also very good for our students
to actually see cancer patients.
That is, that they can connect the research they're doing
in the lab to a real person,
instead of just looking at it from the perspective
of a test tube or working with animals.
So that's a very important part of our research.
I don't think that that's going on in most research labs,
but it's really been effective for us.
And I think it's something that researchers in general
should spend more time doing,
is translating what they're doing to the general public.
Researchers complain about NIH funding being cut
and so forth, and part of the reason for that
is because politically there's not enough pressure
being put on the politicians to keep that going.
The best way to do that is to advocate
for the general public, to advocate for more,
and they're gonna be more inclined to do that
if they understand what research is all about
and how it's leading to progress.
And so I think it's important for researchers
to make that effort to communicate more
with the general public.
I'm David Weinstock, I'm a physician scientist in Boston.
And relatively early in medical school,
I knew that I wanted to be an oncologist,
and a research-based oncologist.
And that was really for three reasons.
The first was that I wanted to do something
that I thought was important.
There's nothing wrong with being a cosmetic dermatologist
or something like that, but it wasn't the job
that I wanted to go home from every night.
I wanted to feel like I was really contributing
something meaningful.
And I consider it a tremendous privilege
to work with patients while they're going through
these unbelievably trying but important moments
in their lives, and to be able to share that with them
and to be able to provide support and guidance
and also learn from them is a tremendous privilege.
The second reason was that oncology,
as many of you I think are recognizing,
has a tremendous opportunity to interface
between the laboratory and the clinic.
And there may be no other field
where advances can come so rapidly.
So on the forefront of cancer genetics,
where I sit, we see something new literally every day.
And sometimes paradigmatic, something completely changing
the way that we think about cancer biology.
And so then I think the third reason was that
because of this very rapid advance,
I recognized relatively early on,
and I think many people also feel this way,
that over the course of my career, certainly,
we're gonna see tremendous advances
in the treatment of cancer.
We're gonna see better outcomes.
We're gonna see less toxicity.
We're gonna see more survival.
And we're gonna see more and more people
living with and being cured of cancer
than what we could have imagined a decade ago.
Now, I think that offers very little solace, in a way,
to people who are living with cancer right now,
and they need a cure today.
And there's no right answer to that.
You can rationalize that these are scourges of humanity,
that every human being, since there were human beings,
has suffered from the risk of developing cancer.
And it's incredible, the advances that we have made.
But again, it offers very little solace
to someone who needs cure now for himself
or for a loved family member or for a friend.
So when I put all that together,
I think the earlier discussion,
maybe we can get back to this later,
about participation in clinical trials,
it's actually emotionally hard for me to think about it.
I mean, I would say, based on the vibe in this room,
there are probably a lot of people here
who idolize Steve Jobs.
And if you look at Steve Jobs,
his personal experience with cancer,
he was diagnosed with pancreatic cancer,
a neuroendocrine type of pancreatic cancer,
that was curable.
And for nine months, he took juices and did acupuncture
and refused to have surgery.
And by the time that he ultimately accepted surgery,
his disease was metastatic.
Now, it's certainly possible
that it might have been micro-metastatic before then,
but I think there's reason to believe
that he's not alive today because of the decisions he made.
Here's a person whose entire life
was dedicated to technology.
And for whatever reason, he was unable
to either believe enough in
or somehow keep himself up to the medical system
and have surgery when he could have had it in the first place.
And if we can't convince Steve Jobs
to participate within the medical system,
we obviously have a lot of work to do.
I'm Louise Feldman, I work at Provena.
I'm a patient navigator assigned to a totally
different aspect here.
I've been in the medical imaging field for 35 years
and had the opportunity, a new program at Provena
for patient navigation.
I jumped on that opportunity.
My mother died of ovarian cancer at a young age
and I saw the need and the support
that these patients need that you all don't see.
And the example, like I had a patient
that just had a diagnosis.
She called me every day crying
and not knowing what to do.
Should I do it, should I not?
You know, and I went through her path reports
and explained how early it was
and because of all the research,
the advancements in early breast cancer is so great
that she did have the surgery last week
and she still calls me about every other day
talking about her experience and about how the support,
having someone there to connect with,
to at least listen to these patients.
They're out there and they're lost sometimes.
They need someone to talk to,
just someone to listen to them, give them ideas.
I have not been involved on the oncology side
and with clinical trials.
I can see now I need to be a little bit more connected
for these patients to at least be able
to know where to guide them.
So it's a learning process for me
and I feel like I can help a lot of people out there
if they ask for it or I can reach out to others
to help them.
So just from my background in medical imaging
and being a person that wants to help others,
that was my whole goal,
why I chose to go into medicine 35 years ago.
We have about 20 minutes for the panel
so I really want to encourage any questions from you guys.
I know you've had to sit and listen for a long time
and now's your chance to ask those burning questions
that you want to hear.
You can ask, I'm sure that Jen and patients
will tell you every little detail
about what it's like to go through treatment
if you want to hear that.
I'm sure we could ask about what the,
well you don't need to ask about the details in the labs
but maybe somebody else, maybe one of us normal people here
would like to do that.
So can we take a moment and just see
if there are any questions?
Hi, I have a question for Jennifer.
So I'm 27, so I'm not that much younger
and when I go to the doctors and I ask about
should I start worrying about things like cancer
and they're like oh, you're too young.
And so I guess my question is to you,
how did you even, how did you realize that you had cancer?
Like how did it all start?
Don't believe you're too young?
I was, I had a baby and was nursing my baby
who was eight months old and happened to notice
I had a lump and thought it was a cloth moth duck.
And thankfully I was not told you're too young.
So I went to his nine month old pediatrician visit.
I said you know I know you treat kids but I found a lump.
And thank God that pediatrician said get it checked out
just for your reassurance.
I'm sure you're fine, you're healthy, you're young.
I joke, I'm like I don't even have cavities.
How can I have cancer, you know, relatively healthy.
But I got it checked out.
Went to Saunders practitioner, she said I'm sure
it's nothing but let's do an ultrasound just in case.
And then Frank's husband who's a radiologist said
the scan looks kind of fishy, let's do a biopsy to be safe.
And sure enough it was breast cancer.
I did, speaking about stages, had a lumpectomy
at clean margins, had no lymph node involvement.
We thought great, we got it all out.
Stage two from the beginning did all the treatment
and so then the cruel irony that it came back.
Once we did get it stable for a little while,
had another lumpectomy, did not get clean margins,
had another recurrence.
Just in December we couldn't get the breast tumor
under control, the bones seemed relatively stable
so had a bilateral mastectomy.
Without reconstruction, it decided if I am living
this life, which statistically I should not be alive,
but I'm not a statistic, I'm a mom and a friend
and a daughter, but if I'm living this life
I'm not spending it, no offense to you guys,
and more doctor's appointments.
So I did not want reconstruction.
And then lo and behold, it pops up in a lymph node
and in the skin.
So it seems like I'm this freak of nature,
whenever we cut it out it comes right back.
But I would say absolutely don't believe
that you're too young for this.
The youngest I know personally was diagnosed at 19.
I had another friend diagnosed at 20 and died at 23.
So yes, statistically we're completely off the charts
in terms of average age of diagnosis.
I believe it's 60, 61, but we're out there
and we're trying to be more active and be heard
because as Leslie showed in that graph,
oh my goodness, childhood cancers and adult cancers
we're making great strides on,
but the young adult population's being left behind
and really looking as researchers, why is that?
And trying to find those answers and make advances there.
So I'm going to ask a very, I think,
potentially charged question.
I'd really be interested in your thoughts
and I wouldn't do it otherwise.
There's obviously, in the last couple of years,
there have been government committees
that have suggested that we come backward
in terms of extensive screening
for different, both PSA and mammogram.
And if you're in a room of scientists,
but also children's brothers, sisters, friends,
mothers and so on, and we all have personal feelings
and we're all also trying to move the science forward
so that we can help as many people as possible.
And so how do you reconcile that in your mind
about whether maybe sometimes it's right
to be doing less rather than more
and maybe sometimes the government might say one thing
but I just can't go along with that.
My personal standpoint, and I'll take Leslie's opinion,
just me, I think it's so important to know your own body.
Mammography failed me all three times.
I came back clean, but luckily,
breast MRI showed up and the biopsy showed up.
I think it's so important to know
what's normal for your body, notice when it changes.
And as young adults, often we're so preconceived
with what we look like, an outward appearance,
and it's so important for us to notice
those internal changes that only we would know
on our bodies.
So I'm really excited to see some of the poster sessions
and looking at what could be coming in the future
in terms of diagnosing earlier
or not using mammography as an option for finding tumors.
But I think right now, it's really,
it's a personal decision, but you only have one body.
You gotta know what it is and how to treat it
and take care of it.
There's, I just came back from a conference in Vegas
on the breast conference, and there are other alternatives.
There's full-field ultrasound scans that they do,
but insurance doesn't cover it.
And so some people are not, aren't able,
I'm sure they can, they would,
are not able to pay for that.
And so these things, we gotta get that through
so that they can have that to offer the patients.
There's tumble sensitives for mammography,
which is like a tumble unit that goes through
and takes a slice through the breast.
And these are also, especially for the young women,
because their breasts are dense.
And that's why mammography a lot of times fails,
because you cannot see that on mammography.
So I'm a mammographer also.
In my case, I think I started routine mammographies
at 40, and then I might have had one or two
that were negative.
I found mine myself.
It wasn't even a self-exam.
I think I just, you know, kind of rubbed,
and there it was, just right on top, could feel it.
I don't know why I hadn't noticed it before.
It was like a P, right under my skin.
So I guess the routine mammography kind of,
it didn't work for me.
In fact, a lot of people, this is just anecdotal.
But most of the women I know,
it wasn't how true routine mammography.
I don't like the idea of scaling back.
But in my experience, most of the women,
and it's just me, didn't find it true, routine mammography.
Well, and the women I know are younger.
I mean, in my peer group.
But I still don't like the idea of scaling back.
When I first heard that, it seemed a little wrong to me.
So.
I would agree, because my lump also,
I had my first mammogram when I was 34.
Because when I was getting my routine exam done,
the nurse practitioner was doing the breast exam,
and she's like, so are your breasts normally lumpy?
I seriously know your body, right?
I'm like, ah, yeah, I guess so.
Yeah, I wouldn't call it smooth, you know?
I didn't know how to answer.
And she's like, well, I'm gonna send you down
for a mammogram anyway,
because my mom was a breast cancer survivor,
so insurance wouldn't, it wouldn't matter
that I was under 35, blah, blah, blah.
So I had the mammogram, it was fine,
and I never thought about it again until I was 36,
and I found a four centimeter lump
in that area that she had felt when I was 34.
And at that time, nobody thought to do an ultrasound
or a follow-up, or it was just, I was there,
and then I wasn't there,
and then I was going through chemotherapy.
That's what it felt like.
So yeah, mammography let me down too,
I think, in a long way.
So I think we can't become complacent with the technologies.
It's the best we have right now, but it's not good enough,
and that's why I'm excited when I hear
of the developments that are happening on this campus
with the imaging research that's going on,
because all of my hopes for every future woman
is in that research.
And I often call cancer researchers my heroes,
because they are going to save a lot of people.
So, any other questions?
Yeah.
I'm one of the researchers.
I read an article recently, there was a hesitancy
on the part of drug companies to test multiple drugs
at one time that seemed like they might be more effective,
because if you find anything wrong
or any side effects with one,
then the whole thing is blown.
Is there still this tendency to just do one drug at a time,
or is that, it seems like it could be more effective
if you could have two targets rather than one?
You know, I think that paradigm is changing.
I think they're more willing to go with multiple drugs
at one time, but it certainly was true
for a number of years that they preferred to do only one.
It's still problematic in the FDA
to get approval of a combination of therapies
where neither one of the two therapies
was already FDA approved.
So, if you're trying to add a drug
onto an FDA approved drug,
but there's a huge movement
in the cancer research community
to try to figure this out, and in fact, many people,
so Bill Sellers, who's the head of Nomartus Cancer Research,
who I think is the smartest guy I know,
has said that the company that figures out combinations
is the company that's going to win, basically,
this race to find the best cures.
And there's a company called Combinatorics
that all they do is combinations.
So, they take 1,000 different kinds of cancer cell lines
representing every major kind of cancer you can imagine,
and they take 300 compounds, and they do every combination.
So, you can imagine 300 times 300 times 1,000.
You're talking about 90 million different combinations
and very high throughput to try to figure out
what are the right combinations of drugs
that we should be pursuing,
both to get those into the clinic
and also to try to investigate
what's the biology underlying responses
to combinations that you wouldn't necessarily predict.
So, the short answer to your question is,
I think it's moving in the right direction,
and it's still got a long way to go.
And I think from the molecular biology side,
from the researcher's perspective,
we know that the correct way to go is multiple drugs
going to multiple targets at the same time.
So, I think that's the reality of it.
It's a question of getting that information
translated into, through the system,
where it actually is being implemented.
To kind of dovetail on that, for future researchers,
the one thing I would ask from a patient's perspective
is to really look at the quality of life
and how you're impacting that patient.
There was a lot of excitement over Avivulin or Havilin
this last year for breast cancer.
About a year ago, it was released
and extended life on average three months.
So, I tried it last summer.
Had such severe neuropathy,
I couldn't twist the bottle cap off a bottle of water.
My son, who was four at the time,
he couldn't tell my handwriting from his
because he couldn't hold a pen.
I had difficulty walking up stairs
because I had significant atrophy in my muscles.
And it didn't work.
And even if it had worked,
my quality of life was so diminished
that I would have stopped anyway.
So, I think there are some really awesome things
that are breaking and groundbreaking
that are coming out right now.
But I hope you keep that in the back of your mind
that looking how things impact cells, that's great.
But how does it really impact the person in their life
and the lives of their loved ones
and how they're able to maintain that quality of life,
especially when their quantity of life is really uncertain?
As far as we've advanced,
for the most common epithelial tumors,
so breast, cancer, prostate, pancreas, ovarian,
we don't even have a paradigm for curing people
who have metastatic disease.
There's no single or combination therapy
that to any extent can be called curative
once the disease has spread.
So I think what many of us believe
is that it's going to take additional paradigms
and that's going to include
many of the types of approaches we've heard about today,
including targeted genetic therapies and siRNA.
We haven't even discussed immune therapies.
And then traditional chemotherapies
and then targeted therapies against driver oncogenes
and other alterations that we know
are making that cancer behave like a cancer
rather than a normal cell.
So how we're going to put all those therapies together
into a curative cocktail
when so many of them are currently not available
is really a daunting challenge.
But I do believe that that's where the interest is
in the cancer community.
And we've moved beyond the point
where we think we're just going to find a magic bullet
and that one compound or siRNA or immune therapy
is going to be the answer
for a significant number of people.
I think as a researcher,
for all the reasons you said,
we think that early diagnosis is key
to get the disease diagnosed before it metastasizes
because that's when it can be most effectively treated
even with existing therapies.
So I think there's a lot of breakthroughs
being made in the area of diagnostics
that I think is really going to impact the future.
Are there ways that patients can help progress those agendas?
Do you think, from your perspectives?
Well, again, in my opinion,
it still comes back to educating the public
and it's contingent upon researchers like myself
to facilitate people like you
who are willing to get out there
and shake the community up
to see that you have the information you need
to go out and to move things forward in the general public.
We can always say we need more money and things like that.
I think also as researchers,
and probably I don't know if you want to comment on this,
but there's some issues about how the money is being spent.
And I mean, I just came from the AAAS meeting.
There's something in the neighborhood
of 20,000 people at this meeting.
I assume every one of them is being funded
in one way or another.
And I had to keep asking myself the question,
how can it possibly be that this number of people
are being funded with this amount of money
for the last 50 years and we're still not further along?
I've got to believe that some of the money
is not being used in the most effective way.
I don't know exactly how to deal with that issue.
I don't know if there's anything else.
I certainly do not have an answer.
I'd like to think to a certain extent
these are really hard problems.
Really, really hard problems.
There are clearly larger design issues
of cancer research that many smart people
are thinking about.
I mean, if you think about research, it's pointillism.
So it's that form of art where you create a picture
by making a million different points on the canvas
and that somehow creates a picture.
And so it's even more complex than that
because I may be funded to make a certain point,
but halfway through the research I realize
that's actually not what's interesting.
What's really interesting and driving my research
is somewhere actually over here.
And somehow we're all working together
and independently and collaboratively and competitively
and we're trying to create a meaningful picture
of what the biology is and then link that to chemistry
and immunology and everything else
that moves us to new treatments.
I've actually forgotten what the original question was.
The patient, well, you've done a fantastic job.
We can actually ask, see if there are any,
we have what, like four minutes left?
We can actually go.
We could go?
Oh, okay.
Got extra time.
Hi, sorry for so many questions.
So I actually have a question about clinical trials
and I kind of wonder, I mean, hearing what Jennifer
was saying about how hard it is to get into one.
I mean, if you're really desperate,
like why can't clinical trials be open access?
Where if you're really desperate and you kind of know,
well, I may die, but there's some hope,
and I have this medicine for cancer,
that you can go online somewhere
and it has all the different clinical trials
that are compiled and you can just basically
enlist yourself in one and you can be anybody, right?
I mean, is that feasible?
I guess that's what our.
I think that's a wonderful question.
It reminds me of what the original previous question was,
what can we do?
Email your congresspeople and senators
and do it over and over again.
I'm totally confused by why some people are so into
cancer research and other people just do not care
because it affects all of us.
No one doesn't know someone who had cancer
or has cancer or died from cancer.
It's a very strange sense of dissociation from cancer
that I'm sure psychologists could work on for their career
where people, if you hear about a bone marrow drive
for a kid who has leukemia and so on,
people will come out of the woodwork
and donate their blood and so on.
But we have many, many patients with cancer
who refuse to donate their tissue or their blood
as part of the process of their diagnosis
just for a researcher like me to work on.
And I don't know why, there's just a certain lack of trust.
Well, part of that is the legislation
because before the GINA Act was around,
the genetic information, whatever,
that's for protecting our information.
If our insurance companies heard that we are
BRCA1 positive or something,
then they could deny us coverage.
But that doesn't exist.
So policies have helped make it a little bit,
at least easier, sorry.
The answer to your question,
the main answer is this is research.
So this is no different than you
doing a controlled experiment in a way.
And it's very difficult to relate that to human beings
who want to participate in these trials.
But you have to decide what's going to be
in your experiment and you have to follow
what you said you were going to do.
And that's the only way you're going to be able
to interpret your data.
And 364 days instead of 365 days, that is stupid.
But that's the way the trial was written.
And if we start bending, even when we should,
then what does that say about the quality of the research
that we're going to be producing?
My non-scientific perspective,
I think a lot of it also from a pharma company,
it's money-motivated.
I am a real big risk to them.
And so if I was enrolled in a clinical trial
since I'm so heavily pretreated
and their drug didn't work,
that brings their success rate down.
And so I think that's another reason
why they leave the gap so narrow
in order to get into their trials,
which I can understand when I'm able
to personally remove myself from it,
but it's hard to understand on a personal level.
This question may be confusing, so bear with me.
But I wanted to go back to your earlier point
about the pointualism and how that works
with radical research.
We hear about incredible research on the diagnosis side.
You know, we're looking at cancer as a whole.
Here's the different ways we can tell it's there.
Looking at cancer as a whole,
here's different ways we can target the treatment
and get it there.
But I wonder if there's any value
in sort of taking some time,
not focusing on the big picture,
actually getting down to the very narrow.
I mean, we have huge cancer communities,
huge conferences where everyone's focused on cancer.
Is there value in sort of breaking those communities down
and having a community that's focused on just,
you know, this specific part of the pathway?
What I'm trying to say is,
is there value in changing the approach to cancer research?
I think cancer research is a hydra.
There are meetings all the time on the most minutiae,
the tiniest aspects of cancer biology
where people in that field go there
and talk about their particular details.
And then there are these much larger,
you know, 30,000-foot view type of meetings.
There are policy meetings.
So part of having 20,000 people working on cancer
is that you kind of get everything.
But it's a bit unorganized.
You agree?
Yeah, I agree.
I mean, there are detailed meetings.
There are meetings on specific pathways that go on.
The problem with cancer is, as you said before,
it's very complicated because we're dealing with cells
that are highly integrated.
And it's not like you can hit one thing
and not affect something else.
And the cancer cells,
in the background, we need an evolution.
These cells want to survive
like all living things want to survive.
And you can hit them at any one given point,
but they're so robust and so integrated
that they're gonna look for alternative ways to get by
whatever you throw at them.
And so I think that the way we have to approach cancer
is from a holistic,
looking at it as an integrated system.
And how best do we treat integrated systems
as opposed to diseases
like sickle cell anemia,
something that's affected by one single gene?
We know how to deal with those kind of diseases.
But we're not used to dealing with diseases
that are really system-wide and highly integrated.
And that's what's making it so complicated
and so difficult to figure out how to deal with.
So this is for the cancer researchers,
as well as anyone else who might have
any experience with this.
How do you, so for the researchers in particular,
how do you engage members of your research group?
How do you get your students to be involved
and to go out and actually interact with patients
to really drive some of these points home?
Or is that a part of what you try
and instill in your students?
Yeah, well, in our particular case,
we're bringing patients in all the time.
So the students are continually interacting
with the patients.
I don't think that that's typical.
But in our case, I think it's very effective.
I think it's highly motivational for the students.
As I said before, to have patients
come through to see what they're doing
really has an impact on human beings.
And I think it helps motivate them,
helps them to work longer hours
or to get really behind
and get more out of the whole case that we've given them.
I thought that was beer and pizza that did that.
Yeah, there's a big gap between curing cancer
and what a student or postdoc needs to think about
and accomplish to be successful.
A postdoc or a grad student needs publications
and notoriety and advances and so on.
And even if they're working in cancer,
it doesn't mean they don't need to be focused
on trying to cure cancer.
And that's actually a problem
because too often they're thinking about the competition
or how fast I can get this out
or all the other nitty gritty of being a scientist
that don't really have to do with anything.
So I think we try to reinforce in my lab
and in our division that we're there to help patients.
And everything we think about
should be thought in that paradigm.
Many of the people in my lab are funded by agencies
like the American Cancer Society
or Susan Komen or Leukemia and Lymphoma Society.
And those organizations have events
where these graduate students and postdocs
can participate and they can meet a lot of students.
Where my lab actually is used to be in the same building
as where the clinics were.
And so the people in my lab would ride the elevators
with the patients, but unfortunately for us,
not for the patients.
We built a brand new building that's purely clinical
and they've all moved out.
And so now the grad students and the postdocs
really don't see the patients the same way.
And that there's a loss there.
I think the kind of pressures you're talking about
are also felt by the PIs.
You know, I mean, you have to publish to get tenure,
you have to get grants.
And unfortunately, that can lead to a situation
that where a paradigm develops that I'm doing science
to get money rather than I'm getting money to do science.
You know, I mean, it puts the emphasis in the wrong place.
And I mean, I'm just saying this because I've come
into science this, I guess, cancer biology late,
but it appears to me that because it's very expensive
to do this, that in some cases I see units developing
that are constantly thinking about what grant,
what grant can I get out?
Here's a grant, I can get some money with it.
And the motivation is to get the money.
And I keep saying to myself and to them sometimes,
really the goal of this is to get somewhere scientifically.
I mean, it's not, we should think about
is the experiment really worth doing
to advance us scientifically rather than thinking
let's do this because there's a grant out there
that's in this particular area.
But that's a problem that I think
the whole community faces.
And I think we have, because we're pressured
to get money and to produce, sometimes it's easy
to get why we're there in the first place.
We're not there to make money.
We're there to try to get the advance,
the research of cancer to help patients ultimately.
I think that's probably, how long do we go?
Three more minutes.
Three more minutes?
I thought that was a great statement,
so I was gonna cheer it on.
But any other questions?
One last question, yeah.
She's coming.
I just make this comment to maybe inspire our students here.
When you said there's 20,000 people in this room
and after that you were at this conference
and after all this time there's still no cure,
that maybe the answer isn't 100% in medicine.
I believe that cancer is a systemic problem
that requires systemic changes.
And maybe some of the research has to be done
to pair up nutritional changes and exercise
and all that along with medicine.
And being a stage four breast cancer survivor
that went from stage four to remission in nine months
and made those changes, and I'm here to talk about it,
I just felt compelled to make that statement
to maybe try and partner those ideas into research together.
I agree completely with that.
One more question, I guess.
The guys with the microphones are ready to run.
To you.
Since no one brought this up, let me bring this up.
This is food for thought.
So if you go to New York City
and sort of stand outside the subway,
close to Wall Street at about two o'clock in the morning,
you'll see a lot of people wearing ties like I am today
from a couple of weeks ago.
They're coming back from work.
And if you stood there for a few more hours
at about 6.37, you'll see them coming back to work.
These are investment bankers.
And they work really, really long hours
with great dedication to make a little bit of money.
I have not seen a single grad student ever
in my entire career who goes home at two in the morning
and comes back at seven in the morning
unless there's something due the very next day.
So I think we, perhaps as a society,
have placed maybe money ahead of cancer cure,
for example, and other things.
And I have no idea how to change this.
I am, for those in my research group,
I'm not advocating, and I'm not gonna expect you
from more than a minute, but at least
there should be four or five such people.
And quite unfortunately, there aren't, to that extent.
So I've had the same people.
The same people?
You have to go in and come out, and then go out.
Yes.
So I have friends who have done that.
They work 20-odd days, and we're now up to four or five years.
But, you know, in tenure track,
you might still see a few people working 20-odd days,
but not at culture in cancer.
I don't know how to change that.
There are very many dedicated people,
but we're not quite as glamorous as Wall Street.
I completely agree with you.
In fact, before the recession and the Wall Street collapse,
over 50% of Harvard undergraduates were going into finance.
And if I was in leadership at Harvard College,
which I will never be, I would find that shameful.
Absolutely shameful.
And yet that was the state of affairs,
and it says a lot about not just what our society is,
what our culture is, and so on, but about how we,
or our field, I shouldn't say we,
because I don't know that it's within our power,
but our field is not attracting a lot of people
who could make a really big difference.
It's not necessarily that we're not motivating people.
There's a lot of other really talented people
and they're not choosing to be cancer researchers.
And so thinking more about how we can
could make a really big difference.
Great.
Thank you.
I think that is the final wrap.
What's coming next?
Is it a break now?
Yes, a break.
Break.
There are cookies out.
No, I don't know what they are.
Reconvene at 4.45.
Reconvene at 4.45?
All right.
Thank you very much, panelists.
Thank you.